Brakemeier S, Taxeidi S I, Zukunft B, Schmidt D, Gaedeke J, Dürr M, Hansen S, Budde K
Division of Nephrology, Department of Internal Medicine, Charité Campus Mitte, Berlin, Germany.
Department of Hematology, Charité Campus Mitte, Berlin, Germany.
Transplant Proc. 2017 Oct;49(8):1757-1765. doi: 10.1016/j.transproceed.2017.06.033.
Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) has risen in kidney transplant (KT) patients, with no long-term data so far on graft function or survival.
KT patients with ESBL-E-positive urine culture were retrospectively analyzed regarding initial adequate antimicrobial therapy, recurrent infection, transplant function, and survival compared with an ESBL-E-negative KT control cohort.
ESBL-E-positive KT patients (n = 93) were older (55.5 ± 16.1 vs 49.5 ± 16.8 y; P = .001), presented with higher trough levels of cyclosporine and tacrolimus (121 ± 71 vs 102 ± 32 ng/mL [P = .04]; and 7.9 ± 3.3 vs 7.0 ± 2.3 ng/mL [P = .04], respectively), higher dosages of mycophenolate (1,533 ± 670 vs 1,493 ± 436; P = .001), and more acute rejection episodes within 3 months before diagnosis (12.9% vs 0.8%; P < .0001) compared with control subjects (n = 591). Five-year patient survival was superior in control subjects compared with ESBL-E-positive patients (91.2% vs 83.5%; P = .034) but long-term graft function was similar. Hospitalization rates were higher in patients presenting with ESBL-E-related urinary tract infection (UTI) compared with control subjects with ESBL-E-negative UTI (60.3% vs 31.3%; P = .002) but 5-year graft survival was superior in patients presenting with ESBL-E-related UTI (88.6% vs 69.8%; P = .035) compared with control subjects with ESBL-E-negative UTI. Recurrence rates were similar in patients with or without ESBL-E-related UTI. Initial antibiotic treatment was adequate in 41.2% of patients presenting with ESBL-E-related urosepsis, resulting in a reevaluation of antibiotic stewardship in our clinic.
ESBL-E detection in general was associated with higher mortality, but graft survival in patients with ESBL-E-related UTI was significantly better compared with ESBL-E-negative UTI.
产超广谱β-内酰胺酶肠杆菌科细菌(ESBL-E)在肾移植(KT)患者中的感染率有所上升,目前尚无关于移植肾功能或生存率的长期数据。
对尿培养ESBL-E阳性的KT患者进行回顾性分析,比较其初始充分抗菌治疗、反复感染、移植功能和生存率,并与ESBL-E阴性的KT对照队列进行比较。
与对照组(n = 591)相比,ESBL-E阳性的KT患者(n = 93)年龄更大(55.5±16.1岁 vs 49.5±16.8岁;P = .001),环孢素和他克莫司的谷浓度更高(分别为121±71 ng/mL vs 102±32 ng/mL [P = .04];7.9±3.3 ng/mL vs 7.0±2.3 ng/mL [P = .04]),霉酚酸剂量更高(1,533±670 vs 1,493±436;P = .001),且在诊断前3个月内急性排斥反应发作更多(12.9% vs 0.8%;P < .0001)。对照组患者的5年生存率高于ESBL-E阳性患者(91.2% vs 83.5%;P = .034),但长期移植功能相似。与ESBL-E阴性尿路感染的对照组相比,ESBL-E相关尿路感染患者的住院率更高(60.3% vs 31.3%;P = .002),但ESBL-E相关尿路感染患者的5年移植生存率高于ESBL-E阴性尿路感染的对照组(88.6% vs 69.8%;P = .035)。有无ESBL-E相关尿路感染患者的复发率相似。41.2%的ESBL-E相关脓毒症患者初始抗生素治疗充分,这促使我们重新评估了临床的抗生素管理。
总体而言,ESBL-E检测与较高的死亡率相关,但与ESBL-E阴性尿路感染相比,ESBL-E相关尿路感染患者的移植生存率显著更高。